Comparative Bioavailability of Nilotinib 200 mg Hard Capsules: A Single-Dose, Open-Label, Randomized, Four-Sequence, Four-Treatment, Four-Period Crossover Pilot Study in Healthy Subjects.
This research is looking at different formulations of a medicine called Nilotinib, which is used to treat a type of blood cancer called chronic myeloid leukaemia (CML). The main goal is to check how these different versions are absorbed and used by the body. This is called a 'bioequivalence' study. It's a very early-stage trial involving healthy volunteers and focuses on how the medicine moves through the body, rather than treating a specific illness. Understanding these details helps ensure that new versions of medicines are just as effective and safe as the original ones. We are also looking at any side effects people might experience.
At a glance
What is this study about?
This study, called a 'bioequivalence' study, is designed to compare how different versions of a medicine called Nilotinib behave in the body. Nilotinib is a medication used to treat a specific type of blood cancer called chronic myeloid leukaemia (CML). This particular study isn't about treating CML directly, but rather about understanding if a new version of the Nilotinib capsule acts in the same way as an existing one. Think of it like comparing two different brands of the same common painkiller – the goal is to see if they both deliver the medicine to your body in a similar way and at a similar speed.
The main aim is to measure how much of the medicine gets into the blood, how quickly it gets there, and how long it stays in the body. These measurements help ensure that any new or generic version of a medicine will have the same effect as the original. This is a crucial step in developing new medicines, as it helps determine if they will be as effective and safe as the medicines already available.
In addition to checking how the medicine works in the body, the researchers will also be keeping a close eye on safety. This means they will be looking for any side effects or changes in your health that might occur during the study. This early stage of research is important for gathering basic information before a medicine can be used more widely.
Key takeaways
- This study compares different versions of a medicine called Nilotinib.
- It's an early-stage study in healthy volunteers, not for treating illness.
- The main goal is to see how the medicine is absorbed and used by the body.
- Safety will be carefully monitored throughout the study.
- Participation involves taking medicines and having regular tests.
Who may be eligible?
This study is looking for healthy adults to take part. There are no upper age limits, but you must be at least 18 years old to be considered.
Both men and women are welcome to participate. The study aims to get a broad understanding of how the medicine works across different people. The researchers will check your overall health carefully to make sure you are suitable for the study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally in good health?
- Are you available for multiple clinic visits?
- Are you comfortable with having blood tests?
- Are you able to follow specific instructions about taking medication?
What does participation involve?
If you decide to take part, you will receive single doses of different versions of the Nilotinib medicine on four separate occasions. This is a 'crossover' study, meaning you will receive each type of medicine at different times, with breaks in between.
Throughout the study, you will have several visits to the clinic where blood samples will be taken frequently to measure the levels of the medicine in your body. We'll also check your vital signs like blood pressure and heart rate, perform ECGs (heart tracings), and do some general health tests to make sure you're doing well. The total time you'd be involved in the study, including the medication periods and follow-up, would be discussed in detail before you agree to participate.
Potential risks and benefits
Locations (1)
- —UnverifiedPortugal
Common questions
What kind of medicine is Nilotinib?
Nilotinib is a medicine typically used to treat a type of blood cancer called chronic myeloid leukaemia (CML).
Why is this study comparing different versions of the same medicine?
Researchers want to make sure that new forms or generic versions of a medicine work exactly the same way as existing ones in the body.
Will I be treated for cancer in this study?
No, this study is for healthy volunteers and is about understanding how the medicine is absorbed, not about treating an illness.
What does a 'crossover' study mean?
It means you will receive different versions of the medicine at different times, with breaks in between, allowing researchers to compare them fairly in the same person.
What will I have to do if I join the study?
You will take single doses of the medicine at different times, have regular blood tests, and undergo health checks like vital signs and ECGs.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.